Dynamic changes of CTCs in patients with metastatic HR(+)/HER2(-) breast cancer receiving salvage treatment with everolimus/exemestane.
Adult
Aged
Aged, 80 and over
Androstadienes
/ administration & dosage
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Biomarkers, Tumor
/ metabolism
Breast Neoplasms
/ drug therapy
Everolimus
/ administration & dosage
Female
Humans
Middle Aged
Neoplasm Metastasis
Neoplastic Cells, Circulating
/ metabolism
Prognosis
Prospective Studies
Receptor, ErbB-2
/ metabolism
Salvage Therapy
Treatment Outcome
Breast cancer
CTCs
Everolimus
Exemestane
mTOR inhibitor
Journal
Cancer chemotherapy and pharmacology
ISSN: 1432-0843
Titre abrégé: Cancer Chemother Pharmacol
Pays: Germany
ID NLM: 7806519
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
19
09
2020
accepted:
29
12
2020
pubmed:
31
1
2021
medline:
24
6
2021
entrez:
30
1
2021
Statut:
ppublish
Résumé
Detection of CTCs represents a poor prognostic factor in patients with early and metastatic breast cancer (mBC) and treatment with everolimus-exemestane (E/E) is an established effective treatment in hormone receptor-positive/HER2-negative mBC patients. The effect of E/E on CTCs in mBC patients was prospectively investigated. CTCs from 50 pre-treated patients with mBC receiving E/E were analyzed using the CellSearch (CS) platform and triple immunofluorescence (IF) staining for cytokeratin, M30 and Ki67 expression to assess their proliferative and apoptotic status. CTCs (by CS) were detected in 64% of patients before treatment and E/E administration resulted in their decreased prevalence [(n = 18; 36%, p = 0.004) and (n = 7; 19.4%, p = 0.019) post-1st and post-3rd treatment cycle, respectively] whereas it was significantly increased at disease progression (PD: 61%) compared to post-1st and post-3rd cycle (p = 0.049 and p = 0.021, respectively). Ki67-positive CTCs were detected in 60%, 60%, 17% and 50% of patients before treatment, post-1st, post-3rd cycle and at PD, respectively, while the opposite was observed for M30-positive CTCs (0% at baseline, 10% after the 1st cycle, 50% after the 3rd cycle and 0% at PD). The detection of even ≥ 1 CTC/5 ml after one cycle was associated with decreased PFS (3.3 vs 9.0 months, p = 0.025) whereas the detection of even ≥ 2 CTCs at PD was associated with decreased OS (32.4 vs 19.5 months; p = 0.009). The combination of E/E resulted in early elimination of proliferating CTCs in mBC patients and this effect was associated with a favorable clinical outcome.
Identifiants
pubmed: 33515073
doi: 10.1007/s00280-020-04227-5
pii: 10.1007/s00280-020-04227-5
doi:
Substances chimiques
Androstadienes
0
Biomarkers, Tumor
0
Everolimus
9HW64Q8G6G
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
exemestane
NY22HMQ4BX
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
277-287Références
Johnston SR (2015) Enhancing endocrine therapy for hormone receptor-positive advanced breast cancer: cotargeting signaling pathways. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djv212
doi: 10.1093/jnci/djv212
pubmed: 26251289
Miller TW, Balko JM, Arteaga CL (2011) Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 29(33):4452–4461. https://doi.org/10.1200/JCO.2010.34.4879
doi: 10.1200/JCO.2010.34.4879
Sabatini DM (2006) mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 6(9):729–734. https://doi.org/10.1038/nrc1974
doi: 10.1038/nrc1974
pubmed: 16915295
deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM et al (2004) Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res Off J Am Assoc Cancer Res 10(23):8059–8067. https://doi.org/10.1158/1078-0432.CCR-04-0035
doi: 10.1158/1078-0432.CCR-04-0035
Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, O’Reilly T et al (2005) The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120(6):747–759. https://doi.org/10.1016/j.cell.2004.12.040
doi: 10.1016/j.cell.2004.12.040
pubmed: 15797377
Boulay A, Zumstein-Mecker S, Stephan C, Beuvink I, Zilbermann F, Haller R et al (2004) Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Can Res 64(1):252–261
doi: 10.1158/0008-5472.CAN-3554-2
Boulay A, Rudloff J, Ye J, Zumstein-Mecker S, O’Reilly T, Evans DB et al (2005) Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res 11(14):5319–5328. https://doi.org/10.1158/1078-0432.CCR-04-2402
doi: 10.1158/1078-0432.CCR-04-2402
Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T et al (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366(6):520–529. https://doi.org/10.1056/NEJMoa1109653
doi: 10.1056/NEJMoa1109653
pubmed: 22149876
Piccart M, Hortobagyi GN, Campone M, Pritchard KI, Lebrun F, Ito Y et al (2014) Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2dagger. Ann Oncol Off J Eur Soc Med Oncol 25(12):2357–2362. https://doi.org/10.1093/annonc/mdu456
doi: 10.1093/annonc/mdu456
Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, Vogel V et al (2013) Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 31(6):539–544. https://doi.org/10.1038/nbt.2576
doi: 10.1038/nbt.2576
pubmed: 23609047
Fehm T, Sagalowsky A, Clifford E, Beitsch P, Saboorian H, Euhus D et al (2002) Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin Cancer Res Off J Am Assoc Cancer Res 8(7):2073–2084
Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC et al (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351(8):781–791. https://doi.org/10.1056/NEJMoa040766
doi: 10.1056/NEJMoa040766
pubmed: 15317891
Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC et al (2006) Circulating tumor cells versus imaging–predicting overall survival in metastatic breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res 12(21):6403–6409. https://doi.org/10.1158/1078-0432.CCR-05-1769
doi: 10.1158/1078-0432.CCR-05-1769
Welter L, Xu L, McKinley D, Dago AE, KP R, Restrepo-Vassalli S et al (2020) Treatment response and tumor evolution: Lessons from an extended series of multi-analyte liquid biopsies in a metastatic breast cancer patient. Cold Spring Harbor molecular case studies. https://doi.org/10.1101/mcs.a005819
doi: 10.1101/mcs.a005819
pubmed: 33203646
pmcid: 7784493
Agelaki S, Dragolia M, Markonanolaki H, Alkahtani S, Stournaras C, Georgoulias V et al (2017) Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients. Oncotarget 8(3):5309–5322. https://doi.org/10.18632/oncotarget.14144
doi: 10.18632/oncotarget.14144
pubmed: 28029660
Kallergi G, Agelaki S, Papadaki MA, Nasias D, Matikas A, Mavroudis D et al (2015) Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients. Breast Cancer Res BCR 17:113. https://doi.org/10.1186/s13058-015-0624-x
doi: 10.1186/s13058-015-0624-x
pubmed: 26285572
Kallergi G, Aggouraki D, Zacharopoulou N, Stournaras C, Georgoulias V, Martin SS (2018) Evaluation of alpha-tubulin, detyrosinated alpha-tubulin, and vimentin in CTCs: identification of the interaction between CTCs and blood cells through cytoskeletal elements. Breast Cancer Res BCR 20(1):67. https://doi.org/10.1186/s13058-018-0993-z
doi: 10.1186/s13058-018-0993-z
pubmed: 29976237
Kallergi G, Hoffmann O, Bittner AK, Papadimitriou L, Katsarou SD, Zacharopoulou N et al (2020) CXCR4 and JUNB double-positive disseminated tumor cells are detected frequently in breast cancer patients at primary diagnosis. Ther Adv Med Oncol 12:1758835919895754. https://doi.org/10.1177/1758835919895754
doi: 10.1177/1758835919895754
pubmed: 32426042
pmcid: 7222234
Kallergi G, Papadaki MA, Politaki E, Mavroudis D, Georgoulias V, Agelaki S (2011) Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer Res BCR 13(3):R59. https://doi.org/10.1186/bcr2896
doi: 10.1186/bcr2896
pubmed: 21663619
Kallergi G, Konstantinidis G, Markomanolaki H, Papadaki MA, Mavroudis D, Stournaras C et al (2013) Apoptotic circulating tumor cells in early and metastatic breast cancer patients. Mol Cancer Ther 12(9):1886–1895. https://doi.org/10.1158/1535-7163.MCT-12-1167
doi: 10.1158/1535-7163.MCT-12-1167
pubmed: 23778153
Spiliotaki M, Mavroudis D, Kapranou K, Markomanolaki H, Kallergi G, Koinis F et al (2014) Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy. Breast Cancer Res BCR 16(6):485. https://doi.org/10.1186/s13058-014-0485-8
doi: 10.1186/s13058-014-0485-8
pubmed: 25432416
Deutsch TM, Riethdorf S, Nees J, Hartkopf AD, Schonfisch B, Domschke C et al (2016) Impact of apoptotic circulating tumor cells (aCTC) in metastatic breast cancer. Breast Cancer Res Treat 160(2):277–290. https://doi.org/10.1007/s10549-016-3997-3
doi: 10.1007/s10549-016-3997-3
pubmed: 27696083
Hartkopf AD, Wagner P, Wallwiener D, Fehm T, Rothmund R (2011) Changing levels of circulating tumor cells in monitoring chemotherapy response in patients with metastatic breast cancer. Anticancer Res 31(3):979–984
pubmed: 21498725
Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC et al (2006) Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res Off J Am Assoc Cancer Res 12(14 Pt 1):4218–4224. https://doi.org/10.1158/1078-0432.CCR-05-2821
doi: 10.1158/1078-0432.CCR-05-2821
Jansson S, Bendahl PO, Larsson AM, Aaltonen KE, Ryden L (2016) Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort. BMC cancer 16:433. https://doi.org/10.1186/s12885-016-2406-y
doi: 10.1186/s12885-016-2406-y
pubmed: 27390845
pmcid: 4938919
Liu P, Cheng H, Roberts TM, Zhao JJ (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8(8):627–644. https://doi.org/10.1038/nrd2926
doi: 10.1038/nrd2926
pubmed: 19644473
pmcid: 3142564
Pierga JY, Hajage D, Bachelot T, Delaloge S, Brain E, Campone M et al (2012) High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol Off J Eur Soc Med Oncol 23(3):618–624. https://doi.org/10.1093/annonc/mdr263
doi: 10.1093/annonc/mdr263
Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G et al (2014) Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol Off J Am Soc Clin Oncol 32(31):3483–3489. https://doi.org/10.1200/JCO.2014.56.2561
doi: 10.1200/JCO.2014.56.2561
Wallwiener M, Hartkopf AD, Baccelli I, Riethdorf S, Schott S, Pantel K et al (2013) The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. Breast Cancer Res Treat 137(2):503–510. https://doi.org/10.1007/s10549-012-2382-0
doi: 10.1007/s10549-012-2382-0
pubmed: 23271327
Ignatiadis M, Rothe F, Chaboteaux C, Durbecq V, Rouas G, Criscitiello C et al (2011) HER2-positive circulating tumor cells in breast cancer. PLoS ONE 6(1):e15624. https://doi.org/10.1371/journal.pone.0015624
doi: 10.1371/journal.pone.0015624
pubmed: 21264346
pmcid: 3018524
Klein CA, Blankenstein TJ, Schmidt-Kittler O, Petronio M, Polzer B, Stoecklein NH et al (2002) Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 360(9334):683–689. https://doi.org/10.1016/S0140-6736(02)09838-0
doi: 10.1016/S0140-6736(02)09838-0
pubmed: 12241875
Xenidis N, Perraki M, Apostolaki S, Agelaki S, Kalbakis K, Vardakis N et al (2013) Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer. Br J Cancer 108(3):549–556. https://doi.org/10.1038/bjc.2012.597
doi: 10.1038/bjc.2012.597
pubmed: 23329233
pmcid: 3593552
Ignatiadis M, Xenidis N, Perraki M, Apostolaki S, Politaki E, Kafousi M et al (2007) Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 25(33):5194–5202. https://doi.org/10.1200/JCO.2007.11.7762
doi: 10.1200/JCO.2007.11.7762
Ignatiadis M, Kallergi G, Ntoulia M, Perraki M, Apostolaki S, Kafousi M et al (2008) Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res 14(9):2593–2600. https://doi.org/10.1158/1078-0432.CCR-07-4758
doi: 10.1158/1078-0432.CCR-07-4758
Xenidis N, Ignatiadis M, Apostolaki S, Perraki M, Kalbakis K, Agelaki S et al (2009) Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 27(13):2177–2184. https://doi.org/10.1200/JCO.2008.18.0497
doi: 10.1200/JCO.2008.18.0497
Saloustros E, Perraki M, Apostolaki S, Kallergi G, Xyrafas A, Kalbakis K et al (2011) Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse. Breast Cancer Res BCR 13(3):R60. https://doi.org/10.1186/bcr2897
doi: 10.1186/bcr2897
pubmed: 21663668
Tang D, Lahti JM, Kidd VJ (2000) Caspase-8 activation and bid cleavage contribute to MCF7 cellular execution in a caspase-3-dependent manner during staurosporine-mediated apoptosis. J Biol Chem 275(13):9303–9307
doi: 10.1074/jbc.275.13.9303
Ueno T, Toi M, Linder S (2005) Detection of epithelial cell death in the body by cytokeratin 18 measurement. Biomed Pharmacother = Biomedecine & pharmacotherapie 59(Suppl 2):S359–S362
doi: 10.1016/S0753-3322(05)80078-2
Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C et al (2004) Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res Off J Am Assoc Cancer Res 10(20):6897–6904. https://doi.org/10.1158/1078-0432.CCR-04-0378
doi: 10.1158/1078-0432.CCR-04-0378
Shiomi-Mouri Y, Kousaka J, Ando T, Tetsuka R, Nakano S, Yoshida M et al (2016) Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer. Breast Cancer 23(1):120–127. https://doi.org/10.1007/s12282-014-0539-x
doi: 10.1007/s12282-014-0539-x
pubmed: 24906662
Politaki E, Agelaki S, Apostolaki S, Hatzidaki D, Strati A, Koinis F et al (2017) A comparison of three methods for the detection of circulating tumor cells in patients with early and metastatic breast cancer. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol 44(2):594–606. https://doi.org/10.1159/000485115
doi: 10.1159/000485115
Yamashita H, Toyama T, Nishio M, Ando Y, Hamaguchi M, Zhang Z et al (2006) p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer. Breast Cancer Res BCR 8(4):R48. https://doi.org/10.1186/bcr1536
doi: 10.1186/bcr1536
pubmed: 16869955
Sieuwerts AM, Kraan J, Bolt J, van der Spoel P, Elstrodt F, Schutte M et al (2009) Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst 101(1):61–66. https://doi.org/10.1093/jnci/djn419
doi: 10.1093/jnci/djn419
pubmed: 19116383
pmcid: 2639293
Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S (2009) Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res BCR 11(4):R46. https://doi.org/10.1186/bcr2333
doi: 10.1186/bcr2333
pubmed: 19589136